Isomorphic Labs raises $5bn Series C led by Greenoaks and Sequoia
TLDR
- Alphabet's AI drug-discovery spin-out Isomorphic Labs raised a $5bn Series C co-led by Greenoaks and Sequoia Capital.12
- a16z joined as a new investor; the company disclosed no valuation, though Bloomberg reported talks at about $50bn.123
- Isomorphic reports positive preclinical results in oncology and immunology, but has disclosed no clinical programme or assets.14
Isomorphic Labs, the London-based AI drug-design company spun out of Google DeepMind in 2021, announced a $5bn Series C on 17 November.12 The release describes an "oversubscribed round" co-led by Greenoaks and Sequoia Capital, "alongside Andreessen Horowitz (a16z) and several other new investors, with continued significant investment from Alphabet".1 All existing investors took part: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.1 The release does not name the other new investors. Kleiner Perkins, which the release does not list, wrote in its own post: "We are investing in Isomorphic Labs". The post does not state the round or amount.5
Isomorphic did not disclose a valuation.2 Bloomberg reported on 4 November, citing unnamed people, that the company was in talks to raise roughly $5bn at about $50bn, and said the financing "hasn't closed and details could change"; on 8 October it had reported early talks at "at least $40 billion".36 Isomorphic did not respond to Bloomberg's request for comment.3 The $50bn is therefore Bloomberg's report of talks, not a confirmed price for the closed round. BioCentury argued on 16 October that, if the rumours were true, such a number was "incongruent with biotech market comparators".7
Isomorphic's drug design engine, IsoDDE, "unifies a suite of foundational simulation AI models that natively work across multiple therapeutic areas and drug modalities", according to the release.1 The work builds on DeepMind's AlphaFold protein-folding model, and partners include Eli Lilly, Novartis and Johnson & Johnson.2 The company reports "positive preclinical results" in internal oncology and immunology programmes and with partners; these are company claims.1 BioSpace notes that Isomorphic has yet to publicly disclose any assets.4 Fierce Biotech says it has not disclosed detailed preclinical data beyond calling the results "positive".8 Small Molecule News adds that the engine's benchmark claims come from the company's own technical report and have not been through peer review or an independent rerun.9 Proceeds will fund IsoDDE, work in new biology, a partner ecosystem and clinical development infrastructure.1 Demis Hassabis said in January that the company expected its first clinical trials by the end of 2026, Bloomberg recalled.3
The round follows a $2.1bn Series B announced on 12 May 2026, led by Thrive Capital, with Alphabet and GV and new backers MGX, Temasek, CapitalG and the UK Sovereign AI Fund.10 BioSpace dates the first fundraise, $600M, to March 2025 and puts total funding at "at least $7.7 billion"; our own sum of the three rounds also gives $7.7bn.4 BioSpace calls the Series C the largest private biotech round on record, ahead of Altos Labs' $3bn debut in 2022, and BioPharma Dive says it is the largest financing among those it has tracked since 2022.411
Greenoaks founder Neil Mehta called discovering and developing new medicines "an optimization challenge of almost infinite scale".1 Sequoia and Kleiner Perkins took part in the $400M Series C of Chai Discovery, a San Francisco company building AI models for molecular design, in July; Index Ventures led at a company-stated $3.8bn valuation.12
Why it matters: a company with no disclosed clinical programme has closed what BioSpace calls the largest private biotech round on record, on company-reported preclinical results, while the reported $50bn valuation remains unconfirmed.134
Sources
- Isomorphic Labs announces $5 Billion Series C funding (PR Newswire (Isomorphic Labs))
- Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials (TechCrunch)
- Isomorphic Labs in Talks for About $5 Billion in Funding (Bloomberg (via Yahoo Finance))
- Isomorphic Labs breaks biotech VC fundraising record with $5B series C (BioSpace)
- Isomorphic Labs: Engineering Biology with AI (Kleiner Perkins)
- Isomorphic Labs in Funding Talks for Over $40 Billion Value (2) (Bloomberg (via Bloomberg Law))
- Valuing a preclinical biotech at $50B is a bad idea - a Perspective (BioCentury)
- Isomorphic Labs raises $5B series C months after $2.1B round (Fierce Biotech)
- Isomorphic Labs Lands $5B Series C Led by Greenoaks, Sequoia (Small Molecule News)
- Isomorphic Labs announces Series B investment round (Isomorphic Labs)
- AI drugmaker Isomorphic restocks with $5B fundraise (BioPharma Dive)
- Chai Discovery Announces $400M Series C to Advance AI-Driven Molecular Design (Business Wire (Chai Discovery))